Overview

Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

Status:
Terminated

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate the efficacy of dutogliptin over 26 weeks (as evidenced by placebo-corrected changes in HbA1c relative to baseline), to demonstrate safety and tolerability of dutogliptin, and to demonstrate changes in fasting plasma glucose over 26 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Phenomix

Collaborator:

Forest Laboratories

Treatments:

Metformin